1556 related articles for article (PubMed ID: 28385467)
1. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
Schey R; Alla SP; Midani D; Parkman HP
Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial.
Yadlapati R; Masihi M; Gyawali CP; Carlson DA; Kahrilas PJ; Nix BD; Jain A; Triggs JR; Vaezi MF; Kia L; Kaizer A; Pandolfino JE
Gastroenterology; 2021 Jan; 160(1):174-182.e1. PubMed ID: 32949568
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
4. [What is the utility of proton pump inhibitor testing in non-cardiac chest pain?].
Huamán JW; Aliaga V; Domenech G; Videla S; Saperas E
Gastroenterol Hepatol; 2014 Oct; 37(8):452-61. PubMed ID: 24725608
[TBL] [Abstract][Full Text] [Related]
5. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
7. [The impact of proton pump inhibitors on esophageal acid exposure in gastroesophageal reflux disease].
Liang XY; Chen WN; Lan L; Wang Q; Lü YW; Lan Y
Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):513-5. PubMed ID: 22943821
[TBL] [Abstract][Full Text] [Related]
8. [The Additional Role of Symptom-Reflux Association Analysis of Diagnosis of Gastroesophageal Reflux Disease Using Bravo Capsule pH Test].
Jung K; Park MI; Park SJ; Moon W; Kim SE; Kim JH
Korean J Gastroenterol; 2017 Oct; 70(4):169-175. PubMed ID: 29060954
[TBL] [Abstract][Full Text] [Related]
9. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
[TBL] [Abstract][Full Text] [Related]
10. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.
Becker V; Grotz S; Schlag C; Nennstiel S; Beitz A; Haller B; Schmid RM; Meining A; Bajbouj M
World J Gastroenterol; 2014 Apr; 20(14):4017-24. PubMed ID: 24744591
[TBL] [Abstract][Full Text] [Related]
11. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
[TBL] [Abstract][Full Text] [Related]
12. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.
Clayton SB; Rife CC; Singh ER; Kalbfleisch JH; Castell DO
Dis Esophagus; 2012; 25(8):682-6. PubMed ID: 22292567
[TBL] [Abstract][Full Text] [Related]
14. Impedance-pH monitoring on medications does not reliably confirm the presence of gastroesophageal reflux disease in patients referred for antireflux surgery.
Ward MA; Dunst CM; Teitelbaum EN; Halpin VJ; Reavis KM; Swanström LL; DeMeester SR
Surg Endosc; 2018 Feb; 32(2):889-894. PubMed ID: 28779252
[TBL] [Abstract][Full Text] [Related]
15. 24 Versus 48-hour bravo pH monitoring.
Chander B; Hanley-Williams N; Deng Y; Sheth A
J Clin Gastroenterol; 2012 Mar; 46(3):197-200. PubMed ID: 21959323
[TBL] [Abstract][Full Text] [Related]
16. BRAVO esophageal pH monitoring: more cost-effective than empiric medical therapy for suspected gastroesophageal reflux.
Afaneh C; Zoghbi V; Finnerty BM; Aronova A; Kleiman D; Ciecierega T; Crawford C; Fahey TJ; Zarnegar R
Surg Endosc; 2016 Aug; 30(8):3454-60. PubMed ID: 26537906
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic measurement of gastric pH associates with persistent acid reflux in patients treated with proton-pump inhibitors for gastroesophageal reflux disease.
Januszewicz W; Hartley J; Waldock W; Roberts G; Alias B; Hobson A; Wernisch L; di Pietro M
United European Gastroenterol J; 2019 Dec; 7(10):1389-1398. PubMed ID: 31807307
[TBL] [Abstract][Full Text] [Related]
18. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
Abdallah J; George N; Yamasaki T; Ganocy S; Fass R
Clin Gastroenterol Hepatol; 2019 May; 17(6):1073-1080.e1. PubMed ID: 29913281
[TBL] [Abstract][Full Text] [Related]
19. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
[TBL] [Abstract][Full Text] [Related]
20. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial.
Bell R; Lipham J; Louie B; Williams V; Luketich J; Hill M; Richards W; Dunst C; Lister D; McDowell-Jacobs L; Reardon P; Woods K; Gould J; Buckley FP; Kothari S; Khaitan L; Smith CD; Park A; Smith C; Jacobsen G; Abbas G; Katz P
Gastrointest Endosc; 2019 Jan; 89(1):14-22.e1. PubMed ID: 30031018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
